Know Cancer

or
forgot password

A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Metastatic Breast Cancer

Thank you

Trial Information

A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer


Inclusion Criteria:



- preserved organ function

- good performance status

- no more than one prior therapy

- no active brain metastasis

Exclusion Criteria:

- No prior capecitabine or oxaliplatin

- no con-current therapy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Overall response rate

Principal Investigator

Sherry Morgan-Meadows

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Wisconsin, Madison

Authority:

United States: Food and Drug Administration

Study ID:

CO 04104

NCT ID:

NCT00204776

Start Date:

March 2005

Completion Date:

November 2006

Related Keywords:

  • Metastatic Breast Cancer
  • Breast Neoplasms

Name

Location
University of Wisconsin Madison,, Wisconsin  53792-5666